FDA Oncology Announcements

AKT1 inhibitor × Clear all

2 Announcements

FDA grants accelerated approval to dordaviprone for diffuse midline glioma

Drug: Modeyso (dordaviprone) · AKT1 inhibitor
Condition: CNS

FDA approves capivasertib with fulvestrant for breast cancer

Trial: CAPItello-291
Drugs: Truqap (capivasertib) · AKT1 inhibitor, fulvestrant · Estrogen receptor inhibitor
Condition: Breast